Bristol Myers Squibb Stock Current Valuation
| BMY Stock | USD 48.93 0.63 1.30% |
Valuation analysis of Bristol Myers Squibb helps investors to measure Bristol Myers' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024. Enterprise Value Multiple is likely to rise to 12.22 in 2024. Fundamental drivers impacting Bristol Myers' valuation include:
Price Book 3.3249 | Enterprise Value 128.2 B | Enterprise Value Ebitda 6.5597 | Price Sales 2.1742 | Forward PE 6.93 |
Overvalued
Today
Please note that Bristol Myers' price fluctuation is very steady at this time. Calculation of the real value of Bristol Myers Squibb is based on 3 months time horizon. Increasing Bristol Myers' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Bristol Myers Squibb is useful when determining the fair value of the Bristol stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Bristol Myers. Since Bristol Myers is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bristol Stock. However, Bristol Myers' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 48.93 | Real 43.3 | Target 71.57 | Hype 48.93 |
The real value of Bristol Stock, also known as its intrinsic value, is the underlying worth of Bristol Myers Squibb Company, which is reflected in its stock price. It is based on Bristol Myers' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Bristol Myers' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bristol Myers' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bristol Myers Squibb helps investors to forecast how Bristol stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bristol Myers more accurately as focusing exclusively on Bristol Myers' fundamentals will not take into account other important factors: Bristol Myers Squibb Company Current Valuation Analysis
Bristol Myers' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bristol Myers Current Valuation | 128.24 B |
Most of Bristol Myers' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bristol Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Bristol Myers is extremely important. It helps to project a fair market value of Bristol Stock properly, considering its historical fundamentals such as Current Valuation. Since Bristol Myers' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bristol Myers' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bristol Myers' interrelated accounts and indicators.
Click cells to compare fundamentals
Bristol Current Valuation Historical Pattern
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers current valuation as a starting point in their analysis.
Bristol Myers Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bristol Myers Squibb has a Current Valuation of 128.24 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
Bristol Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in current valuation category among related companies.
Bristol Myers ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Bristol Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0563 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 128.24 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 78.98 % | ||||
| Number Of Shares Shorted | 35.12 M | ||||
| Price To Earning | 24.88 X | ||||
| Price To Book | 3.32 X | ||||
| Price To Sales | 2.17 X | ||||
| Revenue | 45.01 B | ||||
| Gross Profit | 36.38 B | ||||
| EBITDA | 19.18 B | ||||
| Net Income | 8.04 B | ||||
| Cash And Equivalents | 9.12 B | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 41.46 B | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 14.56 X | ||||
| Cash Flow From Operations | 13.86 B | ||||
| Short Ratio | 1.77 X | ||||
| Earnings Per Share | 3.86 X | ||||
| Price To Earnings To Growth | 2.24 X | ||||
| Target Price | 56.0 | ||||
| Number Of Employees | 34.1 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 99.17 B | ||||
| Total Asset | 95.16 B | ||||
| Retained Earnings | 28.77 B | ||||
| Working Capital | 9.51 B | ||||
| Current Asset | 10.41 B | ||||
| Current Liabilities | 8.02 B | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 2.96 % | ||||
| Net Asset | 95.16 B | ||||
| Last Dividend Paid | 2.31 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
| 0.78 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.63 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Bristol Stock
| 0.57 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.56 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.54 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.49 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.48 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bristol Myers Piotroski F Score and Bristol Myers Altman Z Score analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.